よむ、つかう、まなぶ。
【参考資料5】抗微生物薬適正使用の手引き 第三版 別冊 (47 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第三版
別冊
157. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of
Clostridium difficile intestinal colonization and disease following single-dose antibiotic
prophylaxis in surgery. Antimicrob Agents Chemother. 1991 Jan;35(1):208-210.
158. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021
May;21(1):456.
159. van Prehn J, Reigadas E, Vogelzang EH. et al. European Society of Clinical Microbiology
and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides
difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.
160. Polage CR, Gyorke CE, Kennedy MA. et al. Overdiagnosis of Clostridium difficile Infection in
the Molecular Test Era. JAMA Intern Med. 2015 Nov;175(11):1792-1801.
161. Johnson S, Lavergne V, Skinner AM. et al. Clinical Practice Guideline by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America
(SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection
in Adults. Clin Infect Dis. 2021 Sep;73(5):755-757.
162. Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus
reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or
vancomycin. Clin Infect Dis. 2012 Aug;55 Suppl 2:S104-9.
163. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int
J Antimicrob Agents. 2009 Mar;33 Suppl 1:S33-6.
164. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence
of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006
Mar;42(6):758-764.
165. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163
cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002 Jul;97(7):17691775.
166. Okumura H, Fukushima A, Taieb V, Shoji S, English M. Fidaxomicin compared with
vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile
infection: A network meta-analysis. J Infect Chemother. 2020 Jan;26(1):43-50.
167. Tashiro S, Mihara T, Sasaki M. et al. Oral fidaxomicin versus vancomycin for the treatment of
Clostridioides difficile infection: A systematic review and meta-analysis of randomized
controlled trials. J Infect Chemother. 2022 Nov;28(11):1536-1545.
168. Probiotics revisited. JAMA. 2014 Nov;312(5):1796.
169. Clancy CJ, Nguyen MH. Diagnosing Invasive Candidiasis. J Clin Microbiol. 2018
Apr;56(5):e01909-17.
170. Calandra T, Roberts JA, Antonelli M, Bassetti M, Vincent JL. Diagnosis and management of
invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care. 2016
May;20(1):125.
171. Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of
invasive candidiasis in the intensive care unit. Crit Care. 2010;14(6):244.
172. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct;373(15):14451456.
47
第三版
別冊
157. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of
Clostridium difficile intestinal colonization and disease following single-dose antibiotic
prophylaxis in surgery. Antimicrob Agents Chemother. 1991 Jan;35(1):208-210.
158. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021
May;21(1):456.
159. van Prehn J, Reigadas E, Vogelzang EH. et al. European Society of Clinical Microbiology
and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides
difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.
160. Polage CR, Gyorke CE, Kennedy MA. et al. Overdiagnosis of Clostridium difficile Infection in
the Molecular Test Era. JAMA Intern Med. 2015 Nov;175(11):1792-1801.
161. Johnson S, Lavergne V, Skinner AM. et al. Clinical Practice Guideline by the Infectious
Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America
(SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection
in Adults. Clin Infect Dis. 2021 Sep;73(5):755-757.
162. Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Relapse versus
reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or
vancomycin. Clin Infect Dis. 2012 Aug;55 Suppl 2:S104-9.
163. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int
J Antimicrob Agents. 2009 Mar;33 Suppl 1:S33-6.
164. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence
of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis. 2006
Mar;42(6):758-764.
165. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163
cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002 Jul;97(7):17691775.
166. Okumura H, Fukushima A, Taieb V, Shoji S, English M. Fidaxomicin compared with
vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile
infection: A network meta-analysis. J Infect Chemother. 2020 Jan;26(1):43-50.
167. Tashiro S, Mihara T, Sasaki M. et al. Oral fidaxomicin versus vancomycin for the treatment of
Clostridioides difficile infection: A systematic review and meta-analysis of randomized
controlled trials. J Infect Chemother. 2022 Nov;28(11):1536-1545.
168. Probiotics revisited. JAMA. 2014 Nov;312(5):1796.
169. Clancy CJ, Nguyen MH. Diagnosing Invasive Candidiasis. J Clin Microbiol. 2018
Apr;56(5):e01909-17.
170. Calandra T, Roberts JA, Antonelli M, Bassetti M, Vincent JL. Diagnosis and management of
invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care. 2016
May;20(1):125.
171. Bassetti M, Mikulska M, Viscoli C. Bench-to-bedside review: therapeutic management of
invasive candidiasis in the intensive care unit. Crit Care. 2010;14(6):244.
172. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015 Oct;373(15):14451456.
47